Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Olaparib in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
NCT04579133Phase 2Terminated
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, sponsored by Latin American Cooperative Oncology Group. Started Mar 2021; status: terminated.
02
Drugs
olaparib
Beyond the preview
Go deeper on NCT04579133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579133.